



myCare-204 Clinical Trial

Personalized Therapy Biosimulation for AML Patients

Every patient's tumor has a unique mutation profile.



Standard care guidelines only consider one mutation at a time, resulting in low response rates across cancer types.




Treatment guidelines do not consider mutational interactions and mechanisms of action that often cause drug resistance.



Genome sequencing technology has improved significantly, but today's analysis of the output is inadequate.

Personalized Cancer Therapy Biosimulation considers all the mutations and abnormalities in a patient's tumor.



KNOW response before treatment


SELECT personalized therapies

AVOID ineffective treatments

IMPROVE patient outcomes

Cellworks biosimulation predictions proven to be highly accurate.

myCare-204
Principal Investigators



AML & MDS
90%
Cellworks
Therapy Response
Prediction Accuracy




Dr. Guido Marcucci, MD,
Chair and Professor, Dept. of Hematologic Malignancies Translational Science; Director, Gehr Family Center for Leukemia Research; Chief, Division of Leukemia Research, City of Hope



Dr. Anthony Stein, MD
Hematologist/Oncologist, Co-director, Gehr Family Center for Leukemia Research; Clinical Professor, Division of Leukemia, Dept. of Hematopoietic Cell Transplantation, City of Hope


How does Personalized Therapy Biosimulation work?



Therapy biosimulation reports predict each AML patient's unique response to cancer treatments.

SINGULA™

Identifies the best FDA approved treatment options for a patient with AML, based on the specific cancer mutations in the patient's multi-omic data.



Learn more about the myCare-204 clinical trial at
<https://mycareclinicaltrials.com/AML>